Why and where an HIV cure is needed and how it might be achieved

Nature. 2019 Dec;576(7787):397-405. doi: 10.1038/s41586-019-1841-8. Epub 2019 Dec 18.


Despite considerable global investment, only 60% of people who live with HIV currently receive antiretroviral therapy. The sustainability of current programmes remains unknown and key incidence rates are declining only modestly. Given the complexities and expenses associated with lifelong medication, developing an effective curative intervention is now a global priority. Here we review why and where a cure is needed, and how it might be achieved. We argue for expanding these efforts from resource-rich regions to sub-Saharan Africa and elsewhere: for any intervention to have an effect, region-specific biological, therapeutic and implementation issues must be addressed.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use
  • Combined Modality Therapy*
  • Global Health
  • HIV Infections / drug therapy
  • HIV Infections / epidemiology
  • HIV Infections / immunology
  • HIV Infections / therapy*
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • HIV-1 / immunology
  • Health Resources*
  • Health Services Needs and Demand*
  • Humans
  • Needs Assessment*
  • Receptors, CCR5 / deficiency
  • Receptors, CCR5 / genetics
  • T-Lymphocytes, Cytotoxic / immunology


  • Anti-HIV Agents
  • CCR5 protein, human
  • Receptors, CCR5